Lymphoma
Lymphoma
Advertisement
Leah LawrenceTreatment | January 10, 2023
A recently approved TIW schedule provides new option for patients with ALL or LBL receiving asparaginase.
Read More
Dustin SamplesHematology & Blood Cancer | January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Patrick DalyLymphoma | February 24, 2022
Robert E. Brown, MD, and collaborating researchers from the University of Texas Health Science Center at Houston McGovern ...
Patrick DalyLymphoma | February 24, 2022
A study published in the Journal of Cancer Research and Clinical Oncology discussed outcomes of anti-CD20-based combination ...
Patrick DalyLymphoma | February 24, 2022
Data on diffuse large B-cell lymphoma (DLBCL) from the OncoCollect Lymphoma group registry were recently published in ...
Patrick DalyLymphoma | February 24, 2022
A study published in European Radiology examined the prognostic efficacy of automatic segmentation of diffuse large B-cell ...
Patrick DalyLymphoma | February 24, 2022
According to a study published in the International Journal of Radiation Oncology, Biology, Physics, approximately 50% of ...
Patrick DalyLymphoma | February 9, 2022
According to an article in Translational Cancer Research, data on the clinical outcomes of patients with primary diffuse ...
Patrick DalyLymphoma | February 9, 2022
Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLCBL) have ...
Patrick DalyLymphoma | February 9, 2022
The prevalence of diffuse large b-cell lymphoma (DLBCL) necessitates a thorough understanding of its gene expression profile; ...
Patrick DalyLymphoma | February 9, 2022
Researchers, led by Wenyujing Zhou, aimed to determine the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) ...
Patrick DalyLymphoma | February 9, 2022
Italian researchers, led by Mario Petrini, postulated that subcutaneous (SC) rituximab could be advantageous compared to ...
Patrick DalyLymphoma | January 26, 2022
For patients over 65 years old with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) that have relapsed or ...
Patrick DalyLymphoma | January 26, 2022
Ferroptosis is an iron-dependent programmed cell death caused by lipid peroxidation; however, according to a study published ...
Patrick DalyLymphoma | January 26, 2022
Noting that diffuse large B-cell lymphoma (DLBCL) generally occurs in elderly individuals, researchers Cancan Luo, Han Lie, ...
Patrick DalyLymphoma | January 26, 2022
Citing an unmet clinical need in the identification and understanding of prognostic biomarkers for aggressive B-cell ...
Patrick DalyLymphoma | January 26, 2022
In a study, published in Diagnostics, researchers evaluated whether fludeoxyglucose (FDG) positron emission tomography (PET) ...
Patrick DalyLymphoma | January 12, 2022
Researchers, led by Jie Wang, MD, MS, conducted a network meta-analysis of randomized controlled trials to compare targeted ...
Patrick DalyLymphoma | January 12, 2022
In a study published in the Journal of Oral Pathology & Medicine, researchers examined the prognostic value of varying ...
Patrick DalyLymphoma | January 12, 2022
Noting a lack of data on palliative care in patients with diffuse large b-cell lymphoma (DLBCL), researchers, led by Inimfon ...
Advertisement
Advertisement
Advertisement